A webcast of the fireside chat will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony ...

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences ...

On Wednesday, Piper Sandler reaffirmed its Overweight rating on Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) with a steady price target of $44.00. The firm's positive stance... On Wednesday ...

Antonio Gracias, a director at Harmony Biosciences Holdings , Inc. (NASDAQ:HRMY), has sold a significant portion of the company's stock, according to a recent SEC filing. The... In a recent ...

DelveInsight's 'Myotonic Dystrophy Pipeline Insight 2024' report provides comprehensive global coverage of pipeline myotonic ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Harmony Biosciences Holdings ...

About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have ...

Harmony Biosciences Holdings, Inc. has a 12-month low of $28.14 and a 12-month high of $41.61. Harmony Biosciences ( NASDAQ:HRMY – Get Free Report ) last posted its quarterly earnings data on ...